Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1

Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plants by volume

Sai Life Sciences commences commercial operation of 2nd phase in Bidar

This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility

Emcure to acquire remaining stake in Zuventus Healthcare

The transaction is expected to close in Q2 FY 2026

AbbVie announces new data demonstrating Atogepant achieves superiority in Phase 3 study

TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month

Biocon concludes a Rs 4,500 crore equity fundraise through QIP

The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures

Biogen initiates Phase 3 pediatric study of Omaveloxolone for treatment of Friedreich Ataxia

BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population

USFDA concludes inspection of NATCO’s Pharma Division, Kothur

The company received seven observations in the Form-483

USFDA concludes inspection at Zydus' oncology injectable plant at Ahmedabad

Healthcare Triangle launches Malaysian subsidiary QuantumNexis

QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines

USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad

The company received one observation in the Form-483